Path-for-young project commits to improve care for young women with breast cancer

On 19 October 2024, the Grant Agreement of the Horizon EU-funded Path-for-young project was officially signed, bringing together 25 partners to advance personalized, less toxic breast cancer treatment for premenopausal women. (short version for homepage)

On October 19, 2024, BIG, Unicancer, Warwick University, Gustave Roussy, and 22 other partners signed the Grant Agreement for Path-for-young, a Horizon Europe-supported project coordinated by Dr. Ines Vaz Luis. Building on the OPTIMA clinical trial, this initiative aims to redefine treatment standards for young premenopausal women with high-risk breast cancer.
Up to 55% of women diagnosed with HR+/HER2- breast cancer are under 50. Current treatments, while effective, often result in lasting side effects, especially from chemotherapy. Path-for-young seeks to safely reduce overtreatment using advanced testing, while improving quality of life through digital tools and strong patient involvement.
The study will enroll 3,380 patients across 300 hospitals across Europe, Latin America, and Oceania. Patient enrollment is set to begin in June 2025, with follow-up continuing for at least 3 years, ensuring comprehensive care and monitoring.
The Path-for-young project marks a pivotal moment in advancing breast cancer treatment tailored specifically to younger women, offering new hope for improved outcomes and quality of life.